Cysteinyl Leukotriene Blockade Does Not Prevent Acute Mountain Sickness

Abstract

MOUNTAIN sickness (AMS)is a syndrome that is characterized by headache, anorexia, nausea, vomiting, insomnia, lassitude, and malaise. There is individual variation in susceptibility to the syndrome; however, the hypoxia-induced symptoms are most common in unacclimatized low-altitude residents who rapidly ascend to terrestrial elevations exceeding 2,500 m (10). In addition, the development of AMS appears to be promoted by engaging in physical activities at high altitude (7). The symptoms of AMS commonly appear within 4 to 24 h of exposure, and usually resolve after several days as acclimatization to hypoxia is achieved. AMS is usually self-limited, but may progress into high altitude cerebral edema (HACE) or high altitude pulmonary edema (HAPE), both of which are potentially life threatening.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
May 01, 2004
Accession Number
ADA423394

Entities

People

  • A. Cymerman
  • C. S. Fulco
  • D. Kaminsky
  • L. E. Banderet
  • S. R. Muza

Organizations

  • United States Army Research Institute of Environmental Medicine

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Alkenes
  • Altitude
  • Blood
  • Body Fluids
  • Cardiovascular Physiological Phenomena
  • Cerebral Edema
  • Elevation
  • Health Services
  • Heart Rate
  • High Altitude
  • Information Operations
  • Low Altitude
  • Lung Diseases
  • Measurement
  • Medical Personnel
  • Mountains
  • Sea Level

Fields of Study

  • Medicine

Readers

  • Cardiovascular Physiology
  • Gulf War Illness and Chronic Multisymptom Illness in Veterans.
  • Marine Mammal Biology